Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity

References

• van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity. Eur J General Pract. 1996;2(2):65–70.
   Google Scholar
• Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014;9(7):e102149.
   PubMed Web of Science ®Google Scholar
• Navickas R, Petric VK, Feigl AB, et al. Multimorbidity: What do we know? What should we do? J Comorb. 2016;6(1):4–11.
   PubMedGoogle Scholar
• Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–439.
   PubMed Web of Science ®Google Scholar
• Wan EYF, Chin WY, Yu EYT, et al. The impact of cardiovascular disease and chronic kidney disease on life expectancy and direct medical cost in a 10-year diabetes cohort study. Diabetes Care. 2020;43(8):1750–1758.
   PubMed Web of Science ®Google Scholar
• Hall M, Dondo TB, Yan AT, et al. Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort. PLoS Med. 2018;15(3):e1002501.
   PubMed Web of Science ®Google Scholar
• Nguyen H, Manolova G, Daskalopoulou C, et al. Prevalence of multimorbidity in community settings: a systematic review and Meta-analysis of observational studies. J Comorb. 2019;9:2235042X19870934.
   PubMedGoogle Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377–390.
   PubMed Web of Science ®Google Scholar
• Qureshi A, Friedman A. Comorbidities in dermatology: What's real and what's not. Dermatol Clin. 2019;37(1):65–71. Jan
   PubMed Web of Science ®Google Scholar
• Smith SM, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: Systematic review of interventions in primary care and community settings. BMJ. 2012;345:e5205.
   PubMedGoogle Scholar
• Radner H, Yoshida K, Frits M, et al. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology (Oxford. 2015;54(11):2076–2084.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58(3):443–446.
   PubMed Web of Science ®Google Scholar
• Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3):S101–S11.
   PubMed Web of Science ®Google Scholar
• Prussick R, Unnebrink K, Valdecantos WC. Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis. J Drugs Dermatol. 2015;14(8):864–868.
   PubMed Web of Science ®Google Scholar
• Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007–1011.
   PubMed Web of Science ®Google Scholar
• Reich K, Menter A, Plotnick M, et al. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized clinical trials. Psoriasis Forum. 2007;13a(1):21–27.
   Google Scholar
• Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68–76.
   PubMed Web of Science ®Google Scholar
• Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the corrona psoriasis registry. J Am Acad Dermatol. 2018;78(2):323–232.
   PubMed Web of Science ®Google Scholar
• Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol. 2014;70(4):691–698.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and Meta-analysis. JAMA Dermatol. 2013;149(1):84–91. Jan
   PubMed Web of Science ®Google Scholar
• Takeshita J, Wang S, Shin DB, et al. Effect of psoriasis severity on hypertension control: a Population-Based study in the United Kingdom. JAMA Dermatol. 2015;151(2):161–169.
   PubMed Web of Science ®Google Scholar
• Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–562.
   PubMed Web of Science ®Google Scholar
• Ma C, Harskamp CT, Armstrong EJ, et al. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013;168(3):486–495. Mar
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and Meta-analysis of observational studies. J Hypertens. 2013;31(3):433–442. Mardiscussion 442–3.
   PubMed Web of Science ®Google Scholar
• Sorensen EP, Algzlan H, Au SC, et al. Lower socioeconomic status is associated with decreased therapeutic response to the biologic agents in psoriasis patients. J Drugs Dermatol. 2016;15(2):147–153.
   PubMed Web of Science ®Google Scholar
• Ip B, Cilfone NA, Belkina AC, et al. Th17 cytokines differentiate obesity from obesity-associated type 2 diabetes and promote TNFα production. Obesity (Silver Spring). 2016;24(1):102–112.
   PubMed Web of Science ®Google Scholar
• Van Voorhees AS, Mason MA, Harrold LR, et al. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US corrona psoriasis registry. J Dermatolog Treat. 2021;32(3):302–309.
   PubMed Web of Science ®Google Scholar